Abstract
Background SARS-Cov-2 is a new virus causing a pandemic of primarily respiratory illness designated as Coronavirus Disease 2019 (COVID-19). This disease is associated with excess mortality, particularly among the elderly, raising concerns for public health. It is crucial to identify whether existing medications could protect against adverse outcomes of COVID-19 infection.
Methods We performed a population-based study among members of Clalit Health Services (CHS), the largest healthcare provider in Israel. CHS centrally manages electronic health records (EHR) including medication purchases for over 4.5 million members. Since the disease outbreak through October 10, 2020, 8,681 adult patients aged between 18 and 95 have been hospitalized for COVID-19, among them 3,777 in severe condition. Two case-control matched cohorts were assembled to assess which drugs taken by patients in the month preceding a SARS-CoV-2 positive test, affected risks of COVID-19 hospitalization. Significance of the associations was assessed using Fisher’s exact test and Benjamini-Hochberg correction for multiple testing.
Results Several drugs and pharmacy sold products were significantly associated with reduced odds ratios of SARS-CoV-2 hospitalization: ubiquinone (OR=0.25, p<0.001), ezetimibe (OR=0.51, P<0.001), rosuvastatin (OR=0.75, p<0.001) and flecainide (OR=0.30, p<0.01). Additionally, acquisition of surgical masks, latex gloves and several ophthalmological products were associated with decreased risk for hospitalization.
Conclusion Ubiquinone, ezetimibe and rosuvastatin, all related to the cholesterol synthesis pathway, are associated with reduced hospitalization rate and decreased severity in hospitalized patients. These findings set the basis for specific prospective randomized control trials that should be carried out to carefully assess their protective effects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported in part by the Intramural Research Program of the National Institutes of Health, NCI.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the CHS Institutional Review Board (IRB) with a waiver of informed consent, approval number: COM-0046-20
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This study is based on patients' clinical data and cannot be shared outside of Clalit Health Services
